tetano
Editor, Senior Moderator
Cell Rep
. 2022 Mar 25;110680.
doi: 10.1016/j.celrep.2022.110680. Online ahead of print.
mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
Hye Kyung Lee[SUP] 1 [/SUP], Ludwig Knabl[SUP] 2 [/SUP], Juan I Moliva[SUP] 3 [/SUP], Ludwig Knabl Sr[SUP] 4 [/SUP], Anne P Werner[SUP] 3 [/SUP], Seyhan Boyoglu-Barnum[SUP] 3 [/SUP], Sebastian Kapferer[SUP] 5 [/SUP], Birgit Pateter[SUP] 6 [/SUP], Mary Walter[SUP] 7 [/SUP], Nancy J Sullivan[SUP] 3 [/SUP], Priscilla A Furth[SUP] 8 [/SUP], Lothar Hennighausen[SUP] 9 [/SUP]
Affiliations
Abstract
Knowledge about the impact of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of the elderly on mRNA vaccination response is needed to appropriately address the demand for additional vaccinations in this vulnerable population. Here, we show that octogenarians, a high-risk population, mount a sustained SARS-CoV-2 spike-specific immunoglobulin G (IgG) antibody response for 15 months following infection. This response boosts antibody levels 35-fold upon receiving a single dose of BNT162b2 mRNA vaccine 15 months after recovery from coronavirus disease 2019 (COVID-19). In contrast, antibody responses in naive individuals boost only 6-fold after a second vaccine. Spike-specific angiotensin-converting enzyme 2 (ACE2) antibody binding responses in the previously infected octogenarians following two vaccine doses exceed those found in a naive cohort after two doses. RNA sequencing (RNA-seq) demonstrates activation of interferon-induced genetic programs, which persist only in the previously infected. A preferential increase of specific immunoglobulin G heavy chain variable (IGHV) clonal transcripts that are the basis of neutralizing antibodies is observed only in the previously infected nuns.
Keywords: BNT162b2 vaccine; CP: Microbiology; IGHV clones; Omicron; PBMC; SARS-CoV-2; antibody; cytokine; immune transcriptome; naive versus COVID-19-recovered individuals; neutralization; octogenarian.
. 2022 Mar 25;110680.
doi: 10.1016/j.celrep.2022.110680. Online ahead of print.
mRNA vaccination in octogenarians 15 and 20 months after recovery from COVID-19 elicits robust immune and antibody responses that include Omicron
Hye Kyung Lee[SUP] 1 [/SUP], Ludwig Knabl[SUP] 2 [/SUP], Juan I Moliva[SUP] 3 [/SUP], Ludwig Knabl Sr[SUP] 4 [/SUP], Anne P Werner[SUP] 3 [/SUP], Seyhan Boyoglu-Barnum[SUP] 3 [/SUP], Sebastian Kapferer[SUP] 5 [/SUP], Birgit Pateter[SUP] 6 [/SUP], Mary Walter[SUP] 7 [/SUP], Nancy J Sullivan[SUP] 3 [/SUP], Priscilla A Furth[SUP] 8 [/SUP], Lothar Hennighausen[SUP] 9 [/SUP]
Affiliations
- PMID: 35395191
- PMCID: PMC8947943
- DOI: 10.1016/j.celrep.2022.110680
Abstract
Knowledge about the impact of prior severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection of the elderly on mRNA vaccination response is needed to appropriately address the demand for additional vaccinations in this vulnerable population. Here, we show that octogenarians, a high-risk population, mount a sustained SARS-CoV-2 spike-specific immunoglobulin G (IgG) antibody response for 15 months following infection. This response boosts antibody levels 35-fold upon receiving a single dose of BNT162b2 mRNA vaccine 15 months after recovery from coronavirus disease 2019 (COVID-19). In contrast, antibody responses in naive individuals boost only 6-fold after a second vaccine. Spike-specific angiotensin-converting enzyme 2 (ACE2) antibody binding responses in the previously infected octogenarians following two vaccine doses exceed those found in a naive cohort after two doses. RNA sequencing (RNA-seq) demonstrates activation of interferon-induced genetic programs, which persist only in the previously infected. A preferential increase of specific immunoglobulin G heavy chain variable (IGHV) clonal transcripts that are the basis of neutralizing antibodies is observed only in the previously infected nuns.
Keywords: BNT162b2 vaccine; CP: Microbiology; IGHV clones; Omicron; PBMC; SARS-CoV-2; antibody; cytokine; immune transcriptome; naive versus COVID-19-recovered individuals; neutralization; octogenarian.